Why the study?
Does N-acetylprocainamide-induced QT interval prolongation predict clinical response in patients with stable chronic ventricular arrhythmias?
Does N-acetylprocainamide-induced QT interval prolongation predict clinical response in patients with stable chronic ventricular arrhythmias?
Answers are grounded in this paper and cite their sources.
QT interval changes during initial N-acetylprocainamide administration do not reliably predict subsequent clinical response in patients with ventricular arrhythmias.
We attempted to correlate clinical response with the effects of N-acetylprocainamide (NAPA) on the QT interval in five patients with stable chronic ventricular arrhythmias. A 15 mg/kg dose of NAPA was administered and a pharmacokinetic-pharmacodynamic model was used to relate plasma NAPA concentrations to changes in corrected QT interval (QTc). NAPA volume of distribution, elimination clearance, and elimination half-life averaged 1.37 +/- 0.19 L/kg, 174 +/- 63 ml/min, and 8.2 +/- 1.4 hours, respectively (mean +/- SD), and NAPA renal clearance averaged 1.9 +/- 0.6 times creatinine clearance. QTc prolongation was characterized by a linear-effect model in the first four patients and averaged 2.4 msec for every microgram per milliliter NAPA in a hypothetic biophase. QTc prolongation in patient 5 was exaggerated and was analyzed with an Emax model. Nonetheless, NAPA did not control this patient's arrhythmia. Conversely, patient 1 subsequently developed torsade de pointes even though QTc prolongation in this patient was comparable to that in patients 2 through 4, who responded satisfactorily to NAPA. We conclude that QT interval changes during initial NAPA administration do not reliably predict subsequent clinical response.
No takes yet. Share an insight, caveat, or question.
Piergies et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: